FDA warns GenoGenix over sterility and labeling failures at Boca Raton compounding site

The Food and Drug Administration sent a warning letter dated Jan. 20, 2026, to GenoGenix LLC, a Boca Raton, Florida, facility registered as a 503B outsourcing compounder, saying its drug products failed to meet the conditions that let compounded drugs qualify for exemptions from FDA approval rules and citing practices that "put patients at risk" ^[1].

The letter, numbered 718739, was addressed to CEO Samuel Miron at 2840 NW 2nd Ave, Suites 204 and 205. GenoGenix registered as an outsourcing facility under section 503B of the Federal Food, Drug, and Cosmetic Act on Feb. 4, 2025, and FDA investigators inspected the site from July 14 to July 18, 2025 ^[1]. FDA issued a Form 483 on July 18, 2025, and an amended version on July 31, 2025, then reviewed responses dated Aug. 29, Sept. 30, Oct. 31 and Nov. 30, 2025 ^[1].

FDA acknowledged that the firm has ceased drug production and distribution, and that on July 30, 2025, GenoGenix began a voluntary recall of drug products intended or expected to be sterile that were still within expiry, because of a lack of sterility assurance or microbial contamination ^[1].

Ingredients and label problems

The letter says the facility compounded with bulk drug substances that cannot be used under section 503B: 5-amino-1-methylquinolinium iodide (5-Amino-1MQ) and nicotinamide adenine dinucleotide (NAD+). Neither appears on FDA's 503B bulks list, and neither was used to compound a drug on the federal shortage list, according to the letter ^[1].

FDA listed label omissions. Some products lacked the statement "this is a compounded drug," the facility's name, address and phone number, the established name of the drug, the dosage form, storage and handling instructions, and the statements "Not for resale" and, where applicable, "Office Use Only." Examples include Glutathione Magnesium, Reconstitution Solution, Epithalon, Rapamycin, Clear Mind 150 and LIPO (MIC) + B ^[1]. One product, Immune Defense Nasal Spray, lacked directions for use and container information for reporting adverse events to FDA's MedWatch program ^[1].

FDA said the firm also failed to submit required reports when it registered in February 2025 and in June 2025 identifying the drugs it compounded in the prior six-month period, and had no documented procedures for reporting adverse events ^[1].

Sterility findings

Investigators described insanitary conditions. Operators blocked first air with gloved hands over open sterile containers, reached into a bag of stoppers and then hand-stoppered vials, and worked in aseptic areas while exposing skin, the letter states. The firm had never conducted media fills and had never performed personnel or environmental monitoring during production. FDA also cited a lack of smoke studies, HEPA filters placed next to ceiling return vents, visible gaps in cleanroom sliding glass doors, and handling of hazardous drugs without adequate containment ^[1]. FDA separately listed current good manufacturing practice violations, including failures tied to 21 CFR 211.113(b), 211.22(a) and (d), 211.192 and 211.42(c)(10)(iv) ^[1].

The letter does not name any GLP-1 medication such as semaglutide or tirzepatide, and it does not describe products sold under "research use only" labeling.

Why it matters for patients

Compounded drugs are not FDA-approved. When a compounder does not meet section 503B conditions, its products lose the exemptions that keep them outside the approval requirements, and labeling may not bear adequate directions for use ^[1]. The practical concern in this letter is sterility: FDA said products made at the site may have been contaminated, which is why the company recalled sterile products within expiry on July 30, 2025 ^[1]. Injections that are not sterile can cause infections.

Labels that skip the "compounded drug" statement and the maker's contact details also leave a patient without an easy way to identify who made a product or to report a problem. The letter does not say how many patients or doses were affected, how the recall was communicated, or whether any injuries have been reported; those details have not been disclosed ^[1].

What happens next

The letter does not state a response deadline or describe further enforcement steps. FDA acknowledged that GenoGenix stopped production and distribution and that the recall was under way ^[1].